Swissmedic has decided to temporarily authorize the placing on the market of this antiviral which has proved to be relatively effective in treating Covid-19.
The antiviral remdesivir, the first drug to be shown to be relatively effective in treating Covid-19, will be authorized in Switzerland to treat patients suffering from this disease, excluding therapeutic trials, the Swissmedic institute announced on Thursday.
“Swissmedic, the Swiss Institute for Therapeutic Products, has decided to temporarily authorize the placing on the market of remdesivir. More patients with Covid-19 can be treated now, ”he said in a statement.
The institute made this decision after “an analysis of the benefit / risk ratio” and the preparations, distributed under the trade name Veklury, “may be used without authorization in Swiss hospitals for the treatment of patients affected by Covid-19” , pending the final decision on whether or not to market, said the press release.
“Conditional placing on the market”
Initially developed for Ebola haemorrhagic fever, this antiviral is the first therapy to have demonstrated some efficacy in patients hospitalized for Covid-19 in a clinical trial of significant size, even if the effect is considered to be modest.
The emergency use of this drug in hospitals has been authorized by the United States, then Japan. Europe should allow it soon. Indeed, the European Medicines Agency (EMA) recommended last week the authorization of a “conditional marketing” of remdesivir within the European Union for seriously ill patients of the new coronavirus.